Wood Edward H, Rao Prethy, Moysidis Stavros N, Dedania Vaidehi S, Elman Michael J, Drenser Kimberly A, Capone Antonio, Trese Michael T
Ophthalmic Surg Lasers Imaging Retina. 2018 Sep 1;49(9):e102-e104. doi: 10.3928/23258160-20180907-16.
Anti-vascular endothelial growth factor (VEGF) therapy is increasing in popularity for treatment of retinopathy of prematurity (ROP). Despite many technical benefits, issues remain prompting further investigation.
Retrospective case report and literature review.
A 42-week-old postmenstrual age female with gestational age of 28 weeks and birth weight of 990 g presented with prominent progression of peripapillary purely tractional atypical stage 4A ROP in both eyes following intravitreal bevacizumab therapy in the right eye only.
The authors present the first reported case, to their knowledge, of a "crunch" phenomenon tractional retinal detachment from fellow eye administration of bevacizumab. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:e102-e104.].
抗血管内皮生长因子（VEGF）疗法在早产儿视网膜病变（ROP）的治疗中越来越受欢迎。尽管有许多技术优势，但问题仍然存在，促使进一步研究。
回顾性病例报告及文献综述。
一名孕42周龄的女性，孕龄28周，出生体重990克，仅右眼接受玻璃体内贝伐单抗治疗后，双眼出现视乳头周围单纯牵拉性非典型4A期ROP显著进展。
据作者所知，本文首次报道了因对侧眼给予贝伐单抗而出现“嘎吱”现象牵拉性视网膜脱离的病例。[《眼科手术、激光与视网膜成像》。2018年；49:e102 - e104。]
